Changing CDMO late in development is not always a warning sign. Sometimes it is the right decision. But it should be managed as a strategic move, not an administrative transfer.
Curapath is pleased to acknowledge the significant progress achieved by Macro Biologics, Inc., whose IND application for Amicidin‑α Surgical Gel has been accepted by the FDA, enabling the initiatio...
ACCIÓ’s Noves Oportunitats de Negoci calls for proposals provide Catalan companies with a supportive framework for analysing and structuring new growth opportunities.
ADaM (Analysis Data Model) is the standard designed to ensure that analysis datasets are reproducible, reviewable, and traceable from tabulation (SDTM) to statistical results.
As the clinical research industry continues to grow, companies are facing increasing pressure to meet strict regulatory requirements while keeping studies moving efficiently. Sponsors today need depen...